348 related articles for article (PubMed ID: 22610084)
1. Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.
Mattern MR; Wu J; Nicholson B
Biochim Biophys Acta; 2012 Nov; 1823(11):2014-21. PubMed ID: 22610084
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
[TBL] [Abstract][Full Text] [Related]
3. Deubiquitinating enzymes as therapeutic targets in cancer.
Lim KH; Baek KH
Curr Pharm Des; 2013; 19(22):4039-52. PubMed ID: 23181570
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of deubiquitinating enzyme inhibitors.
Colland F
Biochem Soc Trans; 2010 Feb; 38(Pt 1):137-43. PubMed ID: 20074048
[TBL] [Abstract][Full Text] [Related]
5. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications.
Burger AM; Seth AK
Eur J Cancer; 2004 Oct; 40(15):2217-29. PubMed ID: 15454246
[TBL] [Abstract][Full Text] [Related]
6. Targeting the proteasome pathway.
Tsukamoto S; Yokosawa H
Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
[TBL] [Abstract][Full Text] [Related]
7. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
[TBL] [Abstract][Full Text] [Related]
8. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
9. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP
Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910
[TBL] [Abstract][Full Text] [Related]
10. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.
Dalla Via L; Nardon C; Fregona D
Future Med Chem; 2012 Mar; 4(4):525-43. PubMed ID: 22416778
[TBL] [Abstract][Full Text] [Related]
11. Targeting Deubiquitinases in Cancer.
Bednash JS; Mallampalli RK
Methods Mol Biol; 2018; 1731():295-305. PubMed ID: 29318562
[TBL] [Abstract][Full Text] [Related]
12. Proteasome: an emerging target for cancer therapy.
Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
[TBL] [Abstract][Full Text] [Related]
13. The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells.
Yerlikaya A; Kanbur E
Curr Drug Targets; 2020; 21(13):1313-1325. PubMed ID: 32448101
[TBL] [Abstract][Full Text] [Related]
14. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy.
Frezza M; Schmitt S; Dou QP
Curr Top Med Chem; 2011 Dec; 11(23):2888-905. PubMed ID: 21824109
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
16. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
17. A patent review of the ubiquitin ligase system: 2015-2018.
Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
[TBL] [Abstract][Full Text] [Related]
18. The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
Yerlikaya A; Kanbur E; Stanley BA; Tümer E
Anticancer Agents Med Chem; 2021; 21(1):20-32. PubMed ID: 32781973
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathways: targeting proteasomal protein degradation in cancer.
Molineaux SM
Clin Cancer Res; 2012 Jan; 18(1):15-20. PubMed ID: 22019514
[TBL] [Abstract][Full Text] [Related]
20. Deubiquitylating enzymes and drug discovery: emerging opportunities.
Harrigan JA; Jacq X; Martin NM; Jackson SP
Nat Rev Drug Discov; 2018 Jan; 17(1):57-78. PubMed ID: 28959952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]